Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
26.3M
-
Shares change
-
+2.2M
-
Total reported value, excl. options
-
$554M
-
Value change
-
+$48.1M
-
Put/Call ratio
-
2.16
-
Number of buys
-
76
-
Number of sells
-
-42
-
Price
-
$21.09
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q1 2018
156 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2018.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.3M shares
of 108M outstanding shares and own 24.36% of the company stock.
Largest 10 shareholders include FMR LLC (3.75M shares), ARK Investment Management LLC (3.6M shares), Atlas Venture Associates IX, LLC (2.28M shares), VANGUARD GROUP INC (2.01M shares), MORGAN STANLEY (1.91M shares), BlackRock Inc. (1.72M shares), STATE STREET CORP (1.54M shares), ORBIMED ADVISORS LLC (1.11M shares), BAKER BROS. ADVISORS LP (834K shares), and Temasek Holdings (Private) Ltd (791K shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.